Genomic Biomarker Testing

Helomics offers a select group of clinically relevant protein expression and genetic mutation tests associated with drug response and disease prognosis. Only well-validated tests are included in our biomarker menu with citations of supporting literature provided in every test report. Physicians can select biomarkers for testing from carefully chosen panels of relevant tests, intuitively organized by cancer pathway and tumor type. Results for these tests are presented in a clear, easy to understand format, including summaries of the clinical relevance of each marker.

Helomics biomarker tests include the

most clinically relevant protein and molecular biomarkers which inform individual patient response and prognosis.

Personalized Medicine IHC and helix pati

Biomarkers included in the Helomics portfolio are supported by current treatment guidelines, research, and insight from key opinion leaders.

Many physicians utilize biomarker test results to:

  • Choose between multiple, equivalent therapies for their patients

  • Make decisions on how aggressively to treat cancer

  • Suggest certain clinical trials for those patients that qualify

The tumor types most frequently tested through Helomics panel are gynecologic cancers, lung cancer, breast cancer, colon cancer, and pancreatic cancer, but the tests that comprise the Helomics Biomarker Panel can be performed on any solid tumor type.

Helomics Genomic Biomarker Panels
GYN

EGFR Pathway

  • KRAS (Mutation)

  • BRAF (Mutation)

  • PI3K (Mutation)

  • HER2

  • PTEN

DNA Repair

  • MMR Panel:

MLH1/MSH2/MSH6/

PMS2​

  • ERCC1

  • BRCA1

  • Topo2α

Angiogenesis

  • VEGF

  • CD31

  • PDGFRβ

Other

  • Ki-67

  • P53

LUNG

EGFR Pathway

  • EGFR (Mutation)

  • KRAS (Mutation)

  • BRAF (Mutation)

  • PI3K (Mutation)

  • PTEN

DNA Repair

  • ERCC1

  • TS

  • Topo2α

  • BRCA1

Angiogenesis

  • VEGF

  • CD31

  • PDGFRβ

Other

  • Ki-67

  • P53

  • ROS1 (FISH) (NSCLC Only)

COLON

EGFR Pathway

  • EGFR (Mutation)

  • KRAS (Mutation)

  • BRAF (Mutation)

  • PI3K (Mutation)

  • PTEN

DNA Repair

  • MMR Panel:

MLH1/MSH2/MSH6/

PMS2​

  • TS

Angiogenesis

  • VEGF

  • CD31

  • PDGFRβ

Other

  • Ki-67

  • P53

PANCREATIC

EGFR Pathway

  • EGFR (Mutation)

  • KRAS (Mutation)

DNA Repair

  • MMR Panel:

MLH1/MSH2/MSH6/

PMS2​

  • TS

  • Topo2α

Angiogenesis

  • VEGF

  • CD31

  • PDGFRβ

Other

  • Ki-67

  • P53

BREAST

EGFR Pathway

  • EGFR (Mutation)

  • PI3K (Mutation)

  • HER2

  • PTEN

DNA Repair

  • TS

  • Topo2α

  • BRCA1

Angiogenesis

  • VEGF

  • CD31

  • PDGFRβ

Other

  • Ki-67

  • P53

  • ER

  • PR

Utilizing Biomarker Results

Helomics biomarker results are presented in a clear, easy to understand format, including summaries of the clinical relevance of each test. Each patient report is generally delivered within 10-14 days of receiving the sample with all required paperwork, including signed test order form.

Hover or click in the gallery below to view pages from a sample report.

BFx_Ovarian_Primary_Page_1

BFx_Ovarian_Primary_Page_1

BFx_Ovarian_Primary_Page_2

BFx_Ovarian_Primary_Page_2

BFx_Ovarian_Primary_Page_3

BFx_Ovarian_Primary_Page_3

BFx_Ovarian_Primary_Page_5

BFx_Ovarian_Primary_Page_5

BFx_Ovarian_Primary_Page_6

BFx_Ovarian_Primary_Page_6

BFx_Ovarian_Primary_Page_7

BFx_Ovarian_Primary_Page_7

Useful, Easy to Read Information

Clinically Relevant: Only markers relevant to your patient's cancer type are included

Literature references provided, demonstrating link between marker and therapy

Well validated: All markers have strong clinical evidence supporting their use: many are included in guidelines

Results can be used in both the primary and recurrent settings